{
    "clinical_study": {
        "@rank": "89170", 
        "arm_group": [
            {
                "arm_group_label": "DermaPure\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "DermaPure\u2122 in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing  and appropriate off-loading footwear."
            }, 
            {
                "arm_group_label": "Standard care", 
                "arm_group_type": "Sham Comparator", 
                "description": "Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear."
            }
        ], 
        "brief_summary": {
            "textblock": "This study has been designed to help determine how safe and effective DermaPure\u2122 may be in\n      treating hard-to-heal diabetic foot ulcers compared to the current standard of care."
        }, 
        "brief_title": "A Comparative Efficacy Study of DermaPure\u2122 to Treat Diabetic Foot Ulcers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Foot Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "detailed_description": {
            "textblock": "DermaPure\u2122 is a decellularized dermal skin substitute using the Tissue Regenix dCELL\u00ae\n      patented Technology to remove cells and other components from human and animal tissue while\n      maintaining the native structural and biomechanical properties. The primary objective of the\n      study is to establish the wound healing performance and safety of DermaPure\u2122 over a 12 week\n      period, when administered to \"hard to heal\" chronic, neuropathic diabetic foot ulcers. This\n      study has been designed to compare the performance of DermaPure\u2122 (in combination with\n      standard care) versus standard care alone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 or Type 2 diabetes with HbA1c \u226412%\n\n          -  Adequate perfusion\n\n          -  A full thickness chronic, neuropathic diabetic foot plantar ulcer defined by Texas or\n             Wagner classification.\n\n          -  Target ulcer decreases in size (surface area) by less than 30% in the 2 week\n             screening period.\n\n        Exclusion Criteria:\n\n          -  BMI greater than 45kg/m2.\n\n          -  Presence of infection\n\n          -  Presence of necrosis, purulence or sinus tracts that cannot be removed by aggressive\n             debridement.\n\n          -  A clinical diagnosis of an active/acute Charcot neuroarthropathy. Inactive/chronic\n             Charcot does not exclude the patient.\n\n          -  Therapy with any investigational agent or drug within 4 weeks preceding the screening\n             visit.\n\n          -  More than 2 weeks treatment with immunosuppressive agents within 3 months of\n             enrollment.\n\n          -  Evidence of malnutrition as confirmed by serum pre-albumin level at screening.\n\n          -  Evidence of drug or alcohol abuse,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081352", 
            "org_study_id": "TRG-H01-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "DermaPure\u2122", 
                "description": "A minimally manipulated human tissue regulated as \"human cells, tissues, and cellular and tissue-based products\" (HCT/Ps)", 
                "intervention_name": "DermaPure\u2122", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard care", 
                "intervention_name": "Standard care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dermis", 
            "Diabetic foot ulcers", 
            "Skin substitutes", 
            "Decellularized"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "contact": {
                    "email": "info@healthy-feet.com", 
                    "last_name": "Barbara J Aung, DPM", 
                    "phone": "520-886-9866"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85710"
                    }, 
                    "name": "Aung FootHealth Clinics & Advanced Wound Healing Center"
                }, 
                "investigator": {
                    "last_name": "Barbara J Aung, DPM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure\u2122 in Patients With \"Hard to Heal\" Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm", 
        "other_outcome": {
            "description": "Percentage reduction in ulcer area and volume, weekly up to Week 18 compared to Week 12 for a subset of subjects who receive first application of DermaPure\u2122 at Week 12 (Crossover arm).", 
            "measure": "Rate of wound healing in crossover arm", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "overall_official": {
            "affiliation": "Aung FootHealth Clinics & Advanced Wound Healing Center", 
            "last_name": "Barbara Aung", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The incidence of full wound closure at or before 12 weeks, where full wound closure is defined as \"100% re-epithelialization, without drainage, that has been confirmed at two study visits up to 14 days apart\".", 
            "measure": "Incidence of wound closure", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage reduction in ulcer area and volume, weekly up to Week 12 compared to baseline.", 
                "measure": "Rate of wound healing", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Cellular profile through histological analysis of wound biopsies at Week 4 compared to baseline", 
                "measure": "Quality of wound healing", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "TRx Wound Care Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TRx Wound Care Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}